导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.72% | 2393/4773 |
| 近一周 | -2.83% | 3225/5462 |
| 近一月 | -4.03% | 2151/5421 |
| 近一季 | -12.18% | 3815/5209 |
| 近半年 | -8.16% | 3315/4920 |
| 近一年 | 2.00% | 2215/4366 |
| 近两年 | 73.07% | 919/2954 |
| 近三年 | 26.97% | 1186/2253 |
| 成立以来 | 23.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.30% 1580/4961 |
16.75% 1528/5312 |
- - |
- - |
| 2025 | 29.25% 1415/4813 |
4.56% 913/3635 |
2.87% 1302/4076 |
19.56% 2131/4524 |
0.51% 1965/4813 |
| 2024 | 2.10% 1986/3463 |
-7.77% 2188/2808 |
-9.24% 2341/3014 |
17.01% 1292/3129 |
4.24% 730/3463 |
| 2023 | -5.54% 751/2656 |
9.35% 409/2280 |
-3.34% 776/2385 |
-7.78% 1623/2515 |
-3.10% 603/2655 |
| 2022 | -21.20% 1016/2207 |
-15.47% 1042/1919 |
3.92% 1074/2016 |
-12.46% 708/2113 |
2.47% 925/2208 |
| 2021 | 24.17% 124/1822 |
-4.79% 888/1255 |
14.48% 255/1330 |
5.28% 283/1466 |
8.20% 159/1822 |
| 2020 | 31.36% 504/1250 |
-1.05% 200/1028 |
18.30% 343/1067 |
10.09% 590/1164 |
1.93% 1013/1184 |
| 2019 | 34.60% 397/1092 |
33.77% 130/754 |
-8.94% 620/804 |
2.96% 276/850 |
7.32% 453/918 |
| 2018 | -35.49% 577/834 |
- - |
- - |
- - |
-11.22% 265/691 |
| 2017 | -13.08% 556/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证1000ETF VS. 长安沪深300非周期A(740101) |